Literature DB >> 9798290

Angiotensin receptor antagonists and ACE inhibitors.

L G Howes1, N Christie.   

Abstract

BACKGROUND: ACE inhibitors are valuable and effective drugs in the treatment of hypertension, heart failure, myocardial infarction and nephropathy. Angiotensin receptor antagonists, which have recently been introduced into clinical practice, have the potential to replace ACE inhibitor therapy in many patients.
OBJECTIVE: To review the mechanisms of action, indications and side effects of ACE inhibitors and angiotensin receptor antagonists and to highlight similarities and differences between the two drug classes. DISCUSSION: Angiotensin receptor antagonists have the theoretical advantage of being more effective in blocking the effects of angiotensin II at angiotensin type I receptors. The potential disadvantage of not potentiating bradykinin may be compensated by the unopposed action of angiotensin II on vascular angiotensin type II receptors, which appear to mediate similar beneficial cardiovascular effects to bradykinin. Angiotensin II receptor antagonists have a lower incidence of adverse effects than ACE inhibitors as they do not produce cough and appear much less likely to produce angioedema. Although ACE inhibitors are the most commonly prescribed antihypertensive drug class in Australia, they are underused for the treatment of heart failure and left ventricular dysfunction following myocardial infarction. Angiotensin receptor antagonists may become alternative therapies to ACE inhibitors in these disorders. However, at present they are only indicated for the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9798290

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  1 in total

Review 1.  Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?

Authors:  Laurence G Howes; Diane Tran
Journal:  Drug Saf       Date:  2002       Impact factor: 5.228

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.